Cancer centers and the National Cancer Institute

Cancer ◽  
1972 ◽  
Vol 29 (4) ◽  
pp. 823-824 ◽  
Author(s):  
Carl G. Baker
Medical Care ◽  
2013 ◽  
Vol 51 (7) ◽  
pp. 606-613 ◽  
Author(s):  
Ryan P. Merkow ◽  
David J. Bentrem ◽  
Jeanette W. Chung ◽  
Jennifer L. Paruch ◽  
Clifford Y. Ko ◽  
...  

2019 ◽  
Vol 42 (4) ◽  
pp. 407-410 ◽  
Author(s):  
Andrew T. Day ◽  
Liyang Tang ◽  
Maher Karam-Hage ◽  
Carole Fakhry

2020 ◽  
pp. 108-116
Author(s):  
Jill S. Barnholtz-Sloan ◽  
Dana E. Rollison ◽  
Amrita Basu ◽  
Alexander D. Borowsky ◽  
Alex Bui ◽  
...  

Cancer Informatics for Cancer Centers (CI4CC) is a grassroots, nonprofit 501c3 organization intended to provide a focused national forum for engagement of senior cancer informatics leaders, primarily aimed at academic cancer centers anywhere in the world but with a special emphasis on the 70 National Cancer Institute–funded cancer centers. Although each of the participating cancer centers is structured differently, and leaders’ titles vary, we know firsthand there are similarities in both the issues we face and the solutions we achieve. As a consortium, we have initiated a dedicated listserv, an open-initiatives program, and targeted biannual face-to-face meetings. These meetings are a place to review our priorities and initiatives, providing a forum for discussion of the strategic and pragmatic issues we, as informatics leaders, individually face at our respective institutions and cancer centers. Here we provide a brief history of the CI4CC organization and meeting highlights from the latest CI4CC meeting that took place in Napa, California from October 14-16, 2019. The focus of this meeting was “intersections between informatics, data science, and population science.” We conclude with a discussion on “hot topics” on the horizon for cancer informatics.


2016 ◽  
Vol 12 (4) ◽  
pp. e396-e404 ◽  
Author(s):  
Kalyan C. Mantripragada ◽  
Adam J. Olszewski ◽  
Andrew Schumacher ◽  
Kimberly Perez ◽  
Ariel Birnbaum ◽  
...  

Purpose: Successful clinical trial accrual targeting uncommon genomic alterations will require broad national participation from both National Cancer Institute (NCI)–designated comprehensive cancer centers and community cancer programs. This report describes the initial experience with clinical trial accrual after next-generation sequencing (NGS) from three affiliated non–NCI-designated cancer programs. Materials and Methods: Clinical trial participation was reviewed after enrollment of the first 200 patients undergoing comprehensive genomic profiling by NGS as part of an institutional intuitional review board–approved protocol at three affiliated hospitals in Rhode Island and was compared with published experience from NCI-designated cancer centers. Results: Patient characteristics included a median age of 64 years, a median of two lines of prior therapy, and a predominance of GI carcinomas (58%). One hundred sixty-four of 200 patients (82%) had adequate tumor for NGS, 95% had genomic alterations identified, and 100% had variants of unknown significance. Fifteen of 164 patients (9.2%) enrolled in genotype-directed clinical trials, and three patients (1.8%) received commercially available targeted agents off clinical trials. The reasons for nonreceipt of NGS-directed therapy were no locally available matching trial (48.6%), ineligibility (33.6%) because of comorbidities or interim clinical deterioration, physician's choice of a different therapy (6.8%), or stable disease (11%). Conclusion: This experience demonstrates that a program enrolling patients in specific targeted agent clinical trials after NGS can be implemented successfully outside of the NCI-designated cancer program network, with comparable accrual rates. This is important because targetable genes have rare mutation rates and clinical trial accrual after NGS is low.


Cancer ◽  
2013 ◽  
Vol 120 (3) ◽  
pp. 399-407 ◽  
Author(s):  
Lyen C. Huang ◽  
Yifei Ma ◽  
Justine V. Ngo ◽  
Kim F. Rhoads

Sign in / Sign up

Export Citation Format

Share Document